4.7 Article

Apigenin, a natural flavonoid, promotes autophagy and ferroptosis in human endometrial carcinoma Ishikawa cells in vitro and in vivo

期刊

FOOD SCIENCE AND HUMAN WELLNESS
卷 12, 期 6, 页码 2242-2251

出版社

KEAI PUBLISHING LTD
DOI: 10.1016/j.fshw.2023.03.0442213-4530

关键词

Flavonoid; Apigenin; Autophagy; Ferroptosis; Ishikawa cells; Tumor growth; Endometrial carcinoma

向作者/读者索取更多资源

Apigenin, a natural flavonoid, has been found to inhibit the growth and spread of endometrial cancer cells by promoting autophagy and ferroptosis. It increases iron and lipid oxidation, depletes glutathione, and regulates the expression of relevant genes and proteins. Additionally, apigenin promotes autophagy by upregulating certain proteins and downregulating others. Finally, it inhibits tumor tissue proliferation and growth through ferroptosis.
Apigenin, a natural flavonoid has been reported against a variety of cancer types. However, it is unclear whether apigenin can promote autophagy and ferroptosis in Ishikawa cells. There are few reports on the mechanism of apigenin on autophagy and ferroptosis of endometrial cancer Ishikawa cells. We found that iron accumulation, lipid peroxidation, glutathione consumption, p62, HMOX1, and ferritin were increased, while, solute carrier family 7 member 11 and glutathione peroxidase 4 were decreased. Ferrostatin-1, an iron-death inhibitor could reverse the effects of apigenin in Ishikawa cells. On the other hand, apigenin could promote autophagy via up-regulating Beclin 1, ULK1, ATG5, ATG13, and LC3B and down-regulating AMPK, mTOR, P70S6K, and ATG4. Furthermore, apigenin could inhibit tumor tissue proliferation and restrict tumor growth via ferroptosis in vivo.(c) 2023 Beijing Academy of Food Sciences. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据